Drug intelligence / Profile preview

SGB-3252

Development stage: Preclinical
Lead developer: Suzhou Shengyin Biopharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

SGB-3252 is an investigational RNA interference (RNAi) therapeutic being developed by Suzhou Shengyin Biopharmaceutical (SanegeneBio) for the treatment of hereditary hemorrhagic telangiectasia (HHT) and heavy menstrual bleeding (HMB). Utilizing SanegeneBio's proprietary LEAD (Liver-targeting Efficient siRNA Delivery) platform, SGB-3252 is designed to specifically target and silence the expression of the plasminogen (PLG) gene in the liver. By reducing the levels of circulating plasminogen, the precursor to the fibrinolytic enzyme plasmin, the drug aims to inhibit excessive fibrinolysis and stabilize blood clots, thereby reducing bleeding symptoms in patients. The program is currently in the lead identification (Lead ID) stage of development.

Targets

PLG (Plasminogen)

Beyond the preview

Go deeper on SGB-3252.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGB-3252.

Explore the full profile